Roquette
Roquette is a family-owned global leader in plant-based ingredients and a leading provider of pharmaceutical excipients.
ID: 951816932164-26
Lobbying Activity
Meeting with Ulla Schwager (Head of Unit Competition) and Johnson Johnson and
3 Dec 2025 · Exchange of views on developments in the pharmaceutical industry and aspects of competition law and policy enforcement in this industry sector
Meeting with Ioan-Dragos Tudorache (Cabinet of Executive Vice-President Stéphane Séjourné) and Airbus and
18 Sept 2025 · US and EU-China relations, trade agreements, economic security and trade defence measures, upcoming EU initiatives
Meeting with Chiara Galiffa (Cabinet of Commissioner Maroš Šefčovič) and Airbus and
18 Sept 2025 · US and EU-China relations, trade agreements, economic security and trade defence measures, upcoming EU initiatives
Response to Technical updates of the Emissions Trading Scheme (ETS) State aid guidelines
5 Sept 2025
Roquette welcomes the revision of the EU ETS State Aid Guidelines considering it an important tool to support industry decarbonisation in Europe and relieve the burden of high electricity costs for energy-intensive sectors. As a producer of specialty organic chemicals, we support this revision in view of including additional chemical sectors to preserve the competitiveness of Europes energy-intensive industries while supporting their energy transition. Please find attached our position paper.
Read full response8 Jul 2025
ROQUETTE, a leading EU producer of excipients and food ingredients, appreciates the opportunity to contribute to this important consultation, as energy and carbon management are an integral part of the competitiveness of our operations. As an energy-intensive industry, ROQUETTE is taking active steps to decarbonise its 9 EU production sites and is committed to working towards the EU climate targets and carbon neutrality by 2050, aiming to make Europe the first climate-neutral continent. While the achievement of the EU climate targets and environmental sustainability remains paramount, the economic viability of European energy-intensive industry must equally be taken into consideration. In Europe, unprecedented energy prices are increasing the operational costs and causing a competitive disadvantage of European companies vis-à-vis producers in other regions where energy prices remain lower and carbon pricing systems do not exist. ROQUETTE faces today the twin investment challenge of remaining competitive in a global competition while also investing to lower the environmental and carbon footprint of food ingredients and excipients production. The revision of the European Emission Trading System should provide long-term certainty beyond 2030 and ensure that energy-intensive industries comply with GHG emissions reduction targets cost-effectively, without compromising their operational viability and contribution to the EU economic stability. In this context, we call on the European Commission to undertake an industry-oriented approach in the coming ETS revision, while sustaining the integrity of the EU ETS as a cornerstone of the ambitious EU climate policies. The below contribution outlines the necessity of free allowances and long-term support from multiple angles, emphasizing both environmental and economic considerations. To that end, we respectfully encourage the European Commission to reflect on all climate, environmental and economic considerations and embed the following priorities into the upcoming revision of the EU ETS: Secure long-term predictability for decarbonisation investments: by freezing the reduction of free allowances until all of the shortcomings of the CBAM have been resolved. Recognise and support investments of industry in low-carbon technologies and carbon leakage protection towards meeting the agreed climate ambition. Bring immediate energy cost relief: by extending indirect cost compensation in the EU-ETS to cover organic chemistry value chains. Enable global decarbonisation and avoid European deindustrialisation: by fixing and improving the currently incomplete CBAM design with a much-needed export compensation mechanism, preserving fair competition for European companies exporting to global markets. In the absence of equivalent carbon reductions and costs by competitors in third countries, any higher EU climate ambition should be accompanied by a strengthened mechanism to protect against carbon and investment leakage in sectors that cannot pass on unilateral carbon costs without losing market shares, such as starch. If carbon leakage protection measures are phased down too quickly, European producers will face much higher carbon costs than non-EU producers. As starch products are traded on global markets, producers like ROQUETTE are unable to pass on these additional costs to customers without risking a loss of market share to global competitors, while EU consumers ultimately bear the burden through increased prices for final goods. Roquette and Starch producers in Europe need appropriate EU-wide measures to facilitate the necessary investments for maintaining a steady decarbonisation trajectory. With the right support and policies, we can continue to lead globally and play a key role in the EU thriving economy, ensuring the supply of high-quality food ingredients and excipients for EU consumers.
Read full responseMeeting with Claire Bury (Deputy Director-General Health and Food Safety)
4 Apr 2025 · Exchange on the Vision for Agriculture and Food and the Clean Industrial Deal
Response to Critical Medicines Act
27 Feb 2025
Roquette, excipients and APIs producer, appreciates the opportunity to contribute to this important consultation, as APIs and excipients are integral to the formulation of safe and effective medicines, contributing to public health and the EU's strategic autonomy in pharmaceuticals. We welcome the European Commissions initiative to introduce the Critical Medicines Act as a crucial step toward ensuring a stable and resilient pharmaceutical supply chain within the EU. As Roquette, we are a leading producer of pharmaceutical excipients and an API producer within the European Union. We are proud of the robust production capabilities and high-quality standards of the excipients and APIs Made in Europe that we are offering to the market. APIs and excipients are integral to the formulation of safe and effective medicines, contributing to public health and the EU's strategic autonomy in pharmaceuticals, as they ensure the efficacy and safety of medicines produced. As highlighted in the Strategic Report of the Critical Medicines Alliance, European producers, such as Roquette are deeply affected by significant challenges due to a huge competitiveness gap, fierce competition from non-EU manufacturers heavily supported by their governments, and the lack of appreciation for higher environmental and social standards. Without appropriate measures to level the playing field, the EU excipients industry may struggle to maintain its production capacities, potentially leading to dependency on non-EU sources for critical pharmaceutical components. However, with the right support and policies, we can continue to lead globally, ensuring the supply of high-quality excipients essential for pharmaceutical production. In that sense, the Act must aim at reinforcing the role of our manufacturing industry to build a strong EU pharmaceutical supply chain while: Supporting the EU in introducing essential qualitative criteria on environmental impact that support sustainable EU production in public tenders Protecting EU manufacturing facilities from unfair competition from non-EU regions and levelling the playing field by enforcing strict social and environmental standards Allowing EU state aid regulations to support capacity projects within the scope of the CMA. The Critical Medicines Act requires the EU to promptly deliver clear and decisive signals to its industry, which is currently in a highly critical state. For critical medicines, like those mentioned in the EU list of critical molecules (some of which are produced by Roquette in Europe), we are at a juncture if we want to maintain production capacity in 10 years and the ambition level should meet the industry's needs. This is essential for maintaining a competitive and sustainable industry within the EU, preventing complete dependency, and preserving our industrial and health sovereignty. Therefore, we urge the European Commission to consider these recommendations to safeguard the future of our industry and the health and well-being of EU patients. Roquette is committed to working alongside policymakers to contribute to a more self-sufficient and resilient pharmaceutical ecosystem in Europe and a successful implementation of the Critical Medicines Act.
Read full responseMeeting with Valérie Hayer (Member of the European Parliament) and La Coopération Agricole
5 Nov 2024 · Divers
Meeting with Pascal Canfin (Member of the European Parliament) and Unilever and
29 Jun 2023 · Green Deal
Response to Update of list of sustainable biofuel feedstocks
26 Dec 2022
Roquette proposal for the ongoing Annex IX review and its importance for EU climate goals Roquette is a global leader in plant-based ingredients for food, nutrition and health market. The group addresses current and future societal challenges by unlocking the potential of nature through a broad variety of products. With biofuel production, we rely on our experience to develop and anticipate tomorrow solutions for a sustainable mobility. Reaching the EUs net zero target by 2050 requires the decarbonisation of all sectors, including those that are difficult to decarbonise, such as the aviation and maritime sector. Due to their individual characteristics, both aviation and maritime sectors are heavily relying on sustainable fules like biofuels to decarbonise and substitute the use of fossil fuels. In parallel to this review, the EU Commission, Parliament and Council are in the process of finalising the ReFuelEU Aviation and FuelEU Maritime proposals that are both outlining a clear pathway for these sectors to reduce their emissions mainly with sustainable fuels. Therefore, it is imperative that the Commission enlarges the list of raw materials (classified as feedstock) that are considered suitable waste and residue to be processed into sustainable biofuels (Annex IX of the Renewable Energy Directive). By doing so, the European Commission ensures that there are sufficient volumes of locally sources sustainable biomass feedstock available to cover the growing needs for sustainable biofules and avoid imports of biofuels coming from third countries. In that respect, the starch industry and Roquette, as a European leader in this sector, welcome and support the Commission extending the list of potential sources of supply by clarifying the status of waste starch slurry (Part B, new point (f)). In addition, we proposes a further modification to Annex IX, to also allow for the use of dextrose hydrolysate: Current proposal for Part B, new point (o) Dextrose ultrafiltration retentate from sugar refining New proposal Dextrose ultra or Nano filtration retentate from sugar refining And extend to : Dextrose hydrol from sugar refining We provide all the needed details in the attached document.
Read full response